Macrocyclic Peptides Inhibit PD-L1 Interactions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer and infectious diseases, such as those targeting the PD-1/PD-L1 pathway, often rely on monoclonal antibodies that have limitations in accessibility and specificity, and there is a need for alternative immunomodulatory agents that can effectively inhibit the PD-1/PD-L1 and PD-L1/CD80 interactions to enhance immune responses.
Innovation Solution
Development of macrocyclic peptides that specifically bind to PD-L1, inhibiting its interaction with PD-1 and CD80, offering a novel approach to enhance T cell functional activity and stimulate immunity, potentially in various formulations for different administration routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies are used to target PD-1/PD-L1 pathway, then immune response enhancement is achieved, but accessibility and specificity limitations occur
Solution Approach 1:
The patent changes the molecular class parameter from monoclonal antibodies to macrocyclic peptides, which have different structural and functional properties. These peptides maintain the ability to block PD-1/PD-L1 interactions while offering improved accessibility and specificity characteristics, directly resolving the contradiction between reliability and ease of operation.
Solution Approach 2:
The patent employs smaller macrocyclic peptide molecules instead of large monoclonal antibodies. These peptides are more easily manufactured, administered, and cleared from the body, providing a practical alternative that improves accessibility while maintaining therapeutic effectiveness in blocking immune checkpoint interactions.
2Reliability
If macrocyclic peptides are developed to bind PD-L1, then binding potency and interaction blocking are improved, but molecular complexity increases
Solution Approach 1:
The patent designs macrocyclic peptides with segmented structures that specifically target and bind to PD-L1. The cyclic framework provides structural organization that enables high binding potency while the modular peptide sequence allows for rational design and optimization, balancing complexity with functional effectiveness.
Solution Approach 2:
The patent creates composite macrocyclic structures combining amino acid sequences with cyclic constraints. This composite approach integrates the specificity of peptide binding with the stability and potency of cyclic structures, achieving high binding affinity to PD-L1 while maintaining manageable molecular complexity through deliberate structural design.
Data Source
AI summary
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.